Cancer treatment and research communications最新文献

{"title":"Editorial for \"Long-term oncologic outcome of intraoperative radiotherapy (IORT) with low-energy X-rays as a tumor-bed boost in Korean patients with breast cancer\".","authors":"Shayan Sheikhmiri, Mostafa Robatjazi, Seyed Alireza Javadinia, Sara Shenavaei Zare, Iman Jalaimehr, Reza Chaman","doi":"10.1016/j.ctarc.2025.100935","DOIUrl":"https://doi.org/10.1016/j.ctarc.2025.100935","url":null,"abstract":"","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":" ","pages":"100935"},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to: \"Rectal cancer survival and prognostic factors in Iranian population: A retrospective cohort study\" [Cancer Treatment and Research Communications Volume 39, 2024, 100810].","authors":"Seyed Kazem Mirinezhad, Mostafa Akbarzadeh-Khiavi, Farshad Seyednejad, Mohammad Hossein Somi","doi":"10.1016/j.ctarc.2025.100916","DOIUrl":"https://doi.org/10.1016/j.ctarc.2025.100916","url":null,"abstract":"","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":" ","pages":"100916"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of problem-solving skills training on the self-efficacy and self-concept of the adolescent with cancer","authors":"Ali Askari ,&nbsp;Seyedeh Zahra Aemmi ,&nbsp;Hamidreza Behnam Vashani","doi":"10.1016/j.ctarc.2025.100919","DOIUrl":"10.1016/j.ctarc.2025.100919","url":null,"abstract":"<div><h3>Objective</h3><div>Self-efficacy and self-concept can be negatively affected by developmental crises (such as the onset of adolescence) and acquired crises (such as disease). This study aimed to assess the effectiveness of problem-solving skills training on the self-efficacy and self-concept of adolescents diagnosed with cancer.</div></div><div><h3>Methods</h3><div>This randomized clinical trial involved 60 adolescents with cancer at Dr. Sheikh hospital in Mashhad. The intervention group participated in seven sessions of problem-solving skills training. Adolescents in two groups (intervention = 30 and routine care = 30) completed the Muris self-efficacy questionnaire and Piers-Harris self-concept scale at baseline and one month later.</div></div><div><h3>Results</h3><div>The findings revealed significant differences in the changes in self-efficacy and self-concept scores between the two groups after the intervention (p &lt; 0.001). The improvement in self-efficacy and self-concept scores in the intervention group was statistically significant.</div></div><div><h3>Conclusion</h3><div>Problem-solving skills training can enhance self-efficacy and self-concept, thereby improving the mental health of adolescents with cancer by fostering empowerment, increasing positive mood, and enhancing cognitive understanding of their challenges. Nurses can implement this training as a straightforward and cost-effective supportive care strategy for adolescents affected by cancer.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100919"},"PeriodicalIF":0.0,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncological outcomes and locoregional recurrence after fluorescence guided surgery for axillary staging in early breast cancer: A single UK center experience","authors":"Rahul Kanitkar ,&nbsp;Vassilis Pitsinis ,&nbsp;Bushra Riaz ,&nbsp;Alessio Vinci ,&nbsp;Fiona Hogg ,&nbsp;Lee B. Jordan","doi":"10.1016/j.ctarc.2025.100922","DOIUrl":"10.1016/j.ctarc.2025.100922","url":null,"abstract":"<div><div>Sentinel lymph node biopsy (SLNB) is an established standard technique for staging the axilla in clinically node-negative breast cancer patients. This study evaluates the efficacy of a dual tracer technique combining Indocyanine Green (ICG) fluorescence and blue dye for SLNB in early breast cancer patients at a single institution (Perth Royal Infirmary, Scotland). Over an eight-month period, 139 patients with clinically node-negative invasive breast cancer underwent SLNB, achieving a sentinel lymph node identification rate of 98.5%. Among the identified nodes, a node positivity rate of 19.7% was observed. With a median follow-up of 42 months, axillary recurrence was recorded in only 0.9% of patients, alongside local and distant recurrences of 1.8% and 5.5%, respectively. The findings suggest that the ICG and blue dye technique maintains a low axillary recurrence rate comparable to traditional methods, while also addressing logistical challenges posed by the COVID-19 pandemic. This technique offers a promising alternative to radioisotope-based methods and opens new possible routes for non-radioactive axillary staging techniques. Further long-term outcomes are anticipated as the use of ICG as a sole tracer is integrated into routine practice.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100922"},"PeriodicalIF":0.0,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143776821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis and clinical outcome of papilloma neoplasm of the breast: An observational study","authors":"Puttiporn Naowaset","doi":"10.1016/j.ctarc.2025.100900","DOIUrl":"10.1016/j.ctarc.2025.100900","url":null,"abstract":"<div><h3>Objective</h3><div>due to rarity of this subtype, the aim of this study was to investigate the clinicopathological features, treatment, and prognosis of papillary carcinoma of the breast.</div></div><div><h3>Materials and methods</h3><div>The histopathologic reports of all papillary breast lesion from January 1, 2010, to January 31, 2020, at Ramathibodi hospital were retrieved, comprising a total of 544 reports. Of the 133 (24.44%) histopathologically proved papillary lesions, 411 (75.55%) lesions were excluded from this study due to mixed histopathologic type. The clinical characteristics including age, menopausal status, clinical presentation, the presence of mass, presence of suspicious calcification were recorded. Diagnostic and tumor characteristics including immunohistochemistry, Nottingham grade of tumor, pathological stage were recorded. Local and systemic treatment including type of surgery, chemotherapy, radiation therapy, anti-hormonal therapy and targeted therapy were recorded. Prognosis including overall and disease-free survival were recorded.</div></div><div><h3>Results</h3><div>Of 133 papillary lesions, 47 lesions were invasive solid papillary carcinoma, 7 lesions were invasive encapsulated papillary carcinoma, 31 lesions were solid papillary carcinoma, 27 lesions were encapsulated papillary carcinoma, 16 lesions were invasive papillary carcinoma, and 5 lesions were intraductal papillary carcinoma. The mean follow-up period was 64 months, during which we identified 6 cases of recurrence. Additionally, non-cancer-related deaths were observed in 2 patients. There was no significant difference in disease free survival (DFS) among all types, with a rate of 95.49%. Similarly, overall survival (OS) showed no significant difference, with a rate of 98.5%</div></div><div><h3>Conclusion</h3><div>Papillary carcinoma is a rare variant of breast tumor. All papillary carcinomas, including the invasive types, exhibit an excellent prognosis. It is suggested that invasive papillary carcinoma should be considered a subtype with a favorable prognosis, allowing for minimization of treatment accordingly.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100900"},"PeriodicalIF":0.0,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WITHDRAWN: Association between Prostatic Calculi and Prostate Cancer.","authors":"Yaqin Fan, Yang Luan, Liangyong Zhu, Tianbao Huang, Xuefei Ding, Chaoqun Shi, Fei Wang","doi":"10.1016/j.ctarc.2025.100873","DOIUrl":"https://doi.org/10.1016/j.ctarc.2025.100873","url":null,"abstract":"<p><p>This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/policies/article-withdrawal.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":" ","pages":"100873"},"PeriodicalIF":0.0,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of recurrence and survival in multifocal versus unifocal breast cancer patients at a tertiary center: A case-control study","authors":"Mania Beiranvand,&nbsp;Atieh Akbari,&nbsp;Mohamad Esmaeil Akbari","doi":"10.1016/j.ctarc.2025.100894","DOIUrl":"10.1016/j.ctarc.2025.100894","url":null,"abstract":"<div><h3>Purpose</h3><div>Breast cancer, a significant contributor to global cancer incidence, presents varying clinical and pathological profiles. This study aimed to compare clinical and pathological characteristics, survival rates, and recurrence patterns between patients with multifocal (MF) and unifocal (UF) breast cancer who underwent breast-conserving surgery, to identify potential differences that could inform clinical management and treatment strategies.</div></div><div><h3>Methods</h3><div>The study was a retrospective case-control analysis. Patient records from 2006 to 2015 at the Breast Cancer Research Center of Shahid Beheshti University of Medical Sciences were examined. Inclusion criteria encompassed informed consent, stage I-III breast cancer diagnosis, and breast-conserving surgery. Neoadjuvant chemotherapy recipients, patients with incomplete records, and those with treatment non-compliance were excluded. Demographic data, clinical parameters, and pathological findings were collected and analyzed. Patients were categorized into MF and UF groups based on tumor nodule count. Survival and recurrence rates were assessed using Kaplan-Meier analysis and the Log-Rank test.</div></div><div><h3>Results</h3><div>While mean age did not significantly differ between MF (47.36 years) and UF (49.97 years) breast cancer patients, a significant disparity in menarche age was observed (MF: 13.14 years vs. UF: 12.98 years, <em>p</em>= 0.03). Tumor size significantly varied (MF: 3.68 cm vs. UF: 3.21 cm, <em>p</em>= 0.01). However, menopausal status, hormone receptor (ER and PR) status, mortality, in vitro fertilization history, breastfeeding history, recurrence rates, HER2 status, and pathologic grade showed no significant differences between groups. The 5-year overall survival (OS) rates were 89.2 % for MF and 90.5 % for UF (<em>p</em>= 0.45), and the 5-year recurrence-free survival (RFS) rates were 84.7 % for MF and 86.1 % for UF (<em>p</em>= 0.52).</div></div><div><h3>Conclusion</h3><div>This study suggests that multifocal breast cancer is associated with earlier menarche and larger tumor size compared to unifocal breast cancer. Other clinical and pathological parameters, as well as survival and recurrence rates, did not significantly differ between these two groups. These findings highlight the importance of considering multifocality in clinical decision-making, particularly about tumor size and menarche age, while reassuring that survival and recurrence outcomes remain comparable between MF and UF breast cancer patients.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100894"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143641668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of multiple neoadjuvant chemotherapy cycles in patients with advanced epithelial ovarian cancer: A single center experience","authors":"Wala Mehros ,&nbsp;Rowayd Gobouri ,&nbsp;Omar Turkistani ,&nbsp;Abdulaziz Hinnawi ,&nbsp;Omar Alahmary ,&nbsp;Ahmed Shams ,&nbsp;Jaser Tashkandi ,&nbsp;Amal Al Somairi ,&nbsp;Amal Hanjour ,&nbsp;Syed Sameer Aga ,&nbsp;Hatim Al-Jifree","doi":"10.1016/j.ctarc.2025.100904","DOIUrl":"10.1016/j.ctarc.2025.100904","url":null,"abstract":"<div><h3>Aim</h3><div>Three to four cycles of neoadjuvant chemotherapy prior to interval debulking surgery is a common treatment of ovarian cancer. This study aimed to determine the impact of increasing the number of neoadjuvant chemotherapy cycles on overall survival), progression-free survival, and disease responses in patients diagnosed with epithelial ovarian cancer.</div></div><div><h3>Methods</h3><div>Twenty-eight patients who underwent NACT for advanced-stage EOC were enrolled in a retrospective cohort study conducted at Princess Noorah Oncology Center and King Abdulaziz Medical City between 2010 and 2021 and divided into two groups. Patients in the first group received fewer than six cycles of NACT while those the second group were treated with six or more cycles. Differences in the OS, PFS, and NACT responses were compared.</div></div><div><h3>Results</h3><div>The median OS was 22.50 months ([IQR], 35.75 months) among patients in the group who received fewer than six cycles of NACT and 29.5 months (IQR, 28.75 months) for those treated with six cycles or more (<em>P</em> = 0.67). The median PFS was 12 months (IQR, 16) for the group that received fewer than six cycles, and nine months (IQR, 21.5 months) for patients assigned to the group that received six or more cycles (<em>P</em> = 0.88). Six of the patients from the group that received fewer than six cycles of NACT and five of the patients from the group that received six cycles or more achieved a complete response to therapy (<em>P</em> = 0.81).</div></div><div><h3>Conclusion</h3><div>Increasing the number of NACT cycles did not significantly impact OS, PFS, or the overall response to therapy. However, the study's small patient population presents a limitation.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100904"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab","authors":"Giulia Claire Giudice ,&nbsp;Sara Elena Rebuzzi ,&nbsp;Giulia Mazzaschi ,&nbsp;Federica Pecci ,&nbsp;Michele Maffezzoli ,&nbsp;Alessandro Acunzo ,&nbsp;Letizia Gnetti ,&nbsp;Enrico Maria Silini ,&nbsp;Giuseppe Caruso ,&nbsp;Elena Rapacchi ,&nbsp;Pasquale Rescigno ,&nbsp;Giuseppe Fornarini ,&nbsp;Giuseppe Luigi Banna ,&nbsp;Sebastiano Buti","doi":"10.1016/j.ctarc.2025.100927","DOIUrl":"10.1016/j.ctarc.2025.100927","url":null,"abstract":"<div><h3>Background</h3><div>Metastatic renal cell carcinoma (mRCC) has a dismal prognosis. Effective prognostic and predictive factors are needed. A higher haemoglobin (Hb) / red cell distribution width (RDW) ratio is known to be related to better outcomes. Here we evaluated the prognostic value of the Hb/RDW ratio in pre-treated mRCC patients receiving nivolumab.</div></div><div><h3>Material and methods</h3><div>This is a sub-analysis of the retrospective Meet-URO 15 study, on pre-treated patients with mRCC, receiving nivolumab. The first objective was to investigate the prognostic role of Hb/RDW ratio, in terms of overall survival (OS) and progression-free survival (PFS).</div></div><div><h3>Results</h3><div>356 were included in the present analysis. Patients were mainly males with a median age of 63 years. We classified patients in high and low Hb/RDW ratio, according to two different cut-offs: 0.9frequently used in literature, and 0.7, result of the time-dependent AUC analysis.. Median OS and PFS were 22.3 months (95 %CI 19.4–29.0) and 5.6 months (95 %CI 4.74.–7.53), respectively. At univariable analysis, higher Hb/RDW ratio was related to longer OS (<em>p</em> &lt; 0.001) and PFS (<em>p</em> = 0.011); the multivariable model confirmed only the association between a Hb/RDW ratio ≥ 0.7 and better OS.</div></div><div><h3>Conclusions</h3><div>The Hb/RDW ratio is a manageable and practical prognostic tool in patients with cancer; its prognostic value for OS was confirmed in pre-treated mRCC patients, receiving nivolumab, only using a cut-off value derived from a time-dependent AUC.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100927"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143924599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular analysis highlights TREM2 as a discriminating biomarker for patients suffering from pancreatic ductal adenocarcinoma","authors":"Dimitrios Papakonstantinou ,&nbsp;Haiding Wang ,&nbsp;Mohamed-Amine Bani ,&nbsp;Kevin Mulder ,&nbsp;Garett Dunsmore ,&nbsp;Alice Boilève ,&nbsp;Gérôme Jules-Clément ,&nbsp;Leonardo Panunzi ,&nbsp;Leslie Robert de Sousa ,&nbsp;Carlos de la Calle Fabregat ,&nbsp;Marc Deloger ,&nbsp;Nicolas Signolle ,&nbsp;Grégoire Gessain ,&nbsp;Sergey I Nikolaev ,&nbsp;Michel Ducreux ,&nbsp;Antoine Hollebecque ,&nbsp;Florent Ginhoux ,&nbsp;Camille Blériot","doi":"10.1016/j.ctarc.2025.100939","DOIUrl":"10.1016/j.ctarc.2025.100939","url":null,"abstract":"<div><div>Pancreatic cancer is projected to become the second leading cause of cancer-related deaths by 2030, with its mortality continuing to rise, unlike other common cancers such as breast or colorectal. Late-stage diagnosis, often accompanied by metastatic dissemination, drastically impairs patient survival and underscores the urgent need for improved biomarkers to guide therapeutic strategies. While molecular signatures have been proposed to stratify pancreatic cancer patients, their ability to predict outcomes remains limited. In this study, we applied established molecular signatures to our in-house transcriptomic data from a cohort of pancreatic cancer patients. We took advantage of published datasets to construct comprehensive atlases of cells present in primary and metastatic pancreatic cancers. The atlas of metastasis samples, representative of routinely harvested patient biopsies, revealed that monocyte/macrophage signatures provided superior discriminatory power compared to existing molecular classifications. Notably, the abundance of TREM2-expressing macrophages emerged as a significant parameter for stratifying patients. Our findings position TREM2⁺ macrophages as a promising biomarker for pancreatic cancer, with potential to enhance patient stratification and inform the development of targeted therapies. This work highlights the critical role of tumor-associated macrophages in pancreatic cancer progression and lays the groundwork for further functional and translational studies.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100939"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143935132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}